[1]Hou Y Y, Cai Y T, Jia Z M, et al. Risk factors and prevalence of diabetic retinopathy: a protocol for meta-analysis[J]. Medicine (Baltimore), 2020, 99(42): e22695.
[2]Chua J, Lim C X Y, Wong T Y, et al. Diabetic retinopathy in the Asia-Pacific[J]. Asia Pac J Ophthalmol (Phila), 2018, 7(1): 3-16.
[3]Cheung N, Mitchell P, Wong T Y. Diabetic retinopathy[J]. Lancet, 2010, 376(9735): 124-136.
[4]Solomon S D, Chew E, Duh E J, et al. Diabetic retinopathy: a position statement by the American diabetes association[J]. Diabetes Care, 2017, 40(3): 412-418.
[5]Antonetti D A, Silva P S, Stitt A W. Current understanding of the molecular and cellular pathology of diabetic retinopathy[J]. Nat Rev Endocrinol, 2021, 17(4): 195-206.
[6]Simó R, Stitt A W, Gardner T W. Neurodegeneration in diabetic retinopathy: does it really matter?[J]. Diabetologia, 2018, 61(9): 1902-1912.
[7]Klaassen I, Van Noorden C J F, Schlingemann R O. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions[J]. Prog Retin Eye Res, 2013, 34: 19-48.
[8]Brownlee M. The pathobiology of diabetic complications: a unifying mechanism[J]. Diabetes, 2005, 54(6): 1615-1625.
[9]Uribarri J, Stirban A, Sander D, et al. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects[J]. Diabetes Care, 2007, 30(10): 2579-2582.
[10]Limb G A, Hickman-Casey J, Hollifield R D, et al. Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy[J]. Invest Ophthalmol Vis Sci, 1999, 40(10): 2453-2457.
[11]Mizutani M, Kern T S, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy[J]. J Clin Invest, 1996, 97(12): 2883-2890.
[12]Wei L F, Mo W W, Lan S S, et al. GLP-1 RA improves diabetic retinopathy by protecting the blood-retinal barrier through GLP-1R-ROCK-p-MLC signaling pathway[J]. J Diabetes Res, 2022, 2022: 1861940.
[13]Ting K K, Zhao Y, Shen W Y, et al. Therapeutic regulation of VE-cadherin with a novel oligonucleotide drug for diabetic eye complications using retinopathy mouse models[J]. Diabetologia, 2019, 62(2): 322-334.
[14]Trost A, Lange S, Schroedl F, et al. Brain and retinal pericytes: origin, function and role[J]. Front Cell Neurosci, 2016, 10: 20.
[15]Ogura S, Kurata K, Hattori Y, et al. Sustained inflammation after pericyte depletion induces irreversible blood-retina barrier breakdown[J]. JCI Insight, 2017, 2(3): e90905.
[16]Eshaq R S, Aldalati A M Z, Alexander J S, et al. Diabetic retinopathy: breaking the barrier[J]. Pathophysiology, 2017, 24(4): 229-241.
[17]Eleftheriou C G, Ivanova E, Sagdullaev B T. Of neurons and pericytes: the neuro-vascular approach to diabetic retinopathy[J]. Vis Neurosci, 2020, 37: E005.
[18]Hammes H P, Feng Y X, Pfister F, et al. Diabetic retinopathy: targeting vasoregression[J]. Diabetes, 2011, 60(1): 9-16.
[19]Ivanova E, Kovacs-Oller T, Sagdullaev B T. Vascular pericyte impairment and connexin43 gap junction deficit contribute to vasomotor decline in diabetic retinopathy[J]. J Neurosci, 2017, 37(32): 7580-7594.
[20]Pfister F, Feng Y, Vom Hagen F, et al. Pericyte migration: a novel mechanism of pericyte loss in experimental diabetic retinopathy[J]. Diabetes, 2008, 57(9): 2495-2502.
[21]Huang H. Pericyte-endothelial interactions in the retinal microvasculature[J]. Int J Mol Sci, 2020, 21(19): 7413.
[22]Middel C S, Hammes H P, Kroll J. Advancing diabetic retinopathy research: analysis of the neurovascular unit in zebrafish[J]. Cells, 2021, 10(6): 1313.
[23]Eilken H M, Diéguez-Hurtado R, Schmidt I, et al. Pericytes regulate VEGF-induced endothelial sprouting through VEGFR1[J]. Nat Commun, 2017, 8(1): 1574.
[24]Hammes H P. Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond[J]. Diabetologia, 2018, 61(1): 29-38.
[25]Nian S, Lo A C Y, Mi Y J, et al. Neurovascular unit in diabetic retinopathy: pathophysiological roles and potential therapeutical targets[J]. Eye Vis (Lond), 2021, 8(1): 15.
[26]Kinuthia U M, Wolf A, Langmann T. Microglia and inflammatory responses in diabetic retinopathy[J]. Front Immunol, 2020, 11: 564077.
[27]Mugisho O O, Rupenthal I D, Squirrell D M, et al. Intravitreal pro-inflammatory cytokines in non-obese diabetic mice: modelling signs of diabetic retinopathy[J]. PLoS One, 2018, 13(8): e0202156.
|